3,174 results match your criteria Psychopharmacology Bulletin[Journal]


Promoting the Discussion of the Beneficial Effects of Ketamine to Treat Refractory Depression.

Psychopharmacol Bull 2019 Feb;49(1):98-99

Ghosh, MD, Harvard Medical School, Department of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. Viswanath, MD, Valley Anesthesiology and Pain Consultants, Phoenix, Arizona; Creighton University School of Medicine, Omaha, Nebraska; University of Arizona College of Medicine - Phoenix, Phoenix, Arizona.

View Article

Download full-text PDF

Source
February 2019

Cocaine-Induced Psychosis and Asenapine as Treatment: A Case Study.

Psychopharmacol Bull 2019 Feb;49(1):92-97

Palma-Álvarez, MD, Ros-Cucurull, MD, PhD, Ramos-Quiroga, MD, PhD, Psychiatry Service, CIBERSAM, Vall Hebron University Hospital, Barcelona, Spain and Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona, Barcelona, Spain. Roncero, MD, PhD, Psychiatry Service. University of Salamanca Health Care Complex, Institute of Biomedicine. University of Salamanca. Spain. Grau-López, MD, PhD, Psychiatry Service, CIBERSAM, Vall Hebron University Hospital, Barcelona, Spain and Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona, Barcelona, Spain.

Cocaine-induced psychotic disorder (CIPD) is one of the most serious consequences of cocaine use. Despite the high frequency of CIPD, specific treatment for CIPD has been scarcely researched. Although supportive measures are the first approach, antipsychotic use is often necessary due to clinical severity and CIPD consequences. Read More

View Article

Download full-text PDF

Source
February 2019

An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome.

Psychopharmacol Bull 2019 Feb;49(1):84-91

Van Rensburg, MBChB Dip HIV Man(SA), Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Decloedt, MBChB BSc(Hons) FCCP(SA) MMed(Clin Pharm), Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Neuroleptic malignant syndrome is a rare, idiosyncratic emergency associated with exposure to dopamine antagonists, commonly antipsychotic drugs. The typical clinical picture consists of altered consciousness, muscular rigidity, fever, and autonomic instability. While the condition has generally been well described, the pathophysiology is still poorly understood. Read More

View Article

Download full-text PDF

Source
February 2019

Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report.

Psychopharmacol Bull 2019 Feb;49(1):80-83

Soundarrajan, MBBS post graduate student, department of pharmacology, Kasturba medical college, Manipal Academy of Higher Education, Karnataka, India. Chogtu, MD (pharmacology) Associate professor, department of pharmacology, Kasturba medical college, Manipal Academy of Higher Education, Karnataka, India. Krishna, MBBS post graduate student, department of pharmacology, Kasturba medical college, Manipal Academy of Higher Education, Karnataka, India. Kamanth, MD (psychiatry) Senior resident, department of pharmacology, Kasturba medical college, Manipal Academic of Higher Education, Karnataka, India. Murugesan, MBBS post graduate student, department of pharmacology, Kasturba medical college, Manipal Academic of Higher Education, Karnataka, India.

Akathisia is a common movement disorder that occurs as a consequence of antipsychotic therapy. However, its occurrence secondary to risperidone withdrawal has been reported rarely. Reporting of such rare adverse event gains profound importance because changing the antipsychotics is very common in long term management of affective disorders. Read More

View Article

Download full-text PDF

Source
February 2019

Thrombolytic Therapy in Cocaine Users with Ischemic Stroke: A Review of Current Practice.

Psychopharmacol Bull 2019 Feb;49(1):70-79

Siniscalchi, MD, Pisani, Department of Neurology, "Annunziata" Hospital, Cosenza, Italy. De Sarro, Gallelli, Department of Health Science, School of Medicine, University of Catanzaro Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini University Hospital, Catanzaro, Italy. Pacifici, National Centre on Addiction and Doping, Istituto Superiore di Sanita, V.le Regina Elena 299, Rome. Italy. Sanguigni, Department of Neurology, Madonna del Soccorso Hospital, S Benedetto del Tronto, Italy.

Alteplase is the main pharmacological treatment available for intravenous thrombolysis in patients with acute ischemic stroke. Endovascular treatment alone or add-on to intravenous thrombolysis is a valid approach in acute ischemic stroke with cerebral large vessel disease. The most common serious adverse reaction related to alteplase is the development of spontaneous intracerebral hemorrhage and the presence of cerebral small vessel disease may increase this risk, particularly in cocaine users, even if only few data have been published on this topic. Read More

View Article

Download full-text PDF

Source
February 2019

Exercise as a Treatment for Schizophrenia: A Review.

Psychopharmacol Bull 2019 Feb;49(1):56-69

Girdler, MD, Icahn School of Medicine at Mount Sinai, New York, NY. Confino, BS, Department of Psychiatry & Behavioral Sciences, Albert Einstein College of Medicine, Bronx NY. Woesner, MD, Department of Psychiatry & Behavioral Sciences, Albert Einstein College of Medicine, Bronx NY, and Bronx Psychiatric Center, Bronx, NY.

Schizophrenia is a mental disorder that is characterized by progressive cognitive impairment in areas of attention, working memory, and executive functioning. Although no clear etiology of schizophrenia has been discovered, many factors have been identified that contribute to the development of the disease, such as neurotransmitter alterations, decreased synaptic plasticity, and diminished hippocampal volume. Historically, antipsychotic medications have targeted biochemical alterations in the brains of patients with schizophrenia but have been ineffective in alleviating cognitive and hippocampal deficits. Read More

View Article

Download full-text PDF

Source
February 2019

The Impact of Completing Medication Reconciliation and Depression Treatment History in an Outpatient Depression Clinic.

Psychopharmacol Bull 2019 Feb;49(1):44-55

Choi and Storey, PharmD Candidates of 2020, University of Michigan. Parikh, MD, John F. Greden Professor of Depression and Clinical Neuroscience, Professor of Psychiatry, Professor of Health Management and Policy - School of Public Health, Associate Director, University of Michigan Comprehensive Depression Center; Bostwick, PharmD, BCPS, BCPP, Clinical Associate Professor and Associate Chair, Department of Clinical Pharmacy, and Clinical Pharmacist in Psychiatry, Michigan Medicine, University of Michigan.

Objectives: To enhance depression care by improving medication information available prior to initial patient consultations.

Experimental Design And Sample: Single-center, with intervention delivered to all new patient referrals at a tertiary care depression clinic. Trained pharmacy students utilizing a standard script prior to the first consultation visit conducted a medication review and depression treatment telephone assessment. Read More

View Article

Download full-text PDF

Source
February 2019

Paroxetine Vortioxetine for Depressive Symptoms in Postmenopausal Transition: A Preliminary Study.

Psychopharmacol Bull 2019 Feb;49(1):28-43

Callegari, MD, PhD, Associate Professor, Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy. Ielmini, MD, PhD Student, Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy. Caselli, MD, PhD Student, Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy. Lucca, MD, Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy. Isella, MD, Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy. Diurni, MD, PhD, Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy. Pettenon, MD, Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy. Poloni, MD, PhD, Researcher, Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy.

Background: The impact of menopause is a consequence of social, physical and mental changes; hormonal changes play an important role in inducing an increased risk of developing depressive symptoms. It is essential to treat mood and vasomotor symptoms and to prevent their onset to promote an improvement in the quality of life, both in terms of clinical and psychological conditions.

Objective: This observational study aims to compare paroxetine and vortioxetine in a sample of patients affected by postmenopausal depression attending the Anxiety and Depression Clinic in terms of: efficacy in determining clinical remission (HDRS ≤ 7) and tolerability; improvement of autonomic and cognitive symptoms. Read More

View Article

Download full-text PDF

Source
February 2019

Impact of Gabapentin Adjunct use with Benzodiazepines for the Treatment of Alcohol Withdrawal in a Psychiatric Hospital.

Psychopharmacol Bull 2019 Feb;49(1):17-27

Vadiei, Pharm.D., BCPP, Assistant Professor, The University of Arizona, College of Pharmacy Practice and Science, Tucson, AZ. Smith, Pharm.D., BCPP, Associate Professor, Department of Psychiatry, Dell Medical School at The University of Texas at Austin, TX. Walton, MD., Assistant Professor, Department of Psychiatry, Dell Medical School at The University of Texas at Austin, TX. Kjome, MD., Assistant Professor, Department of Psychiatry, Dell Medical School at The University of Texas at Austin, TX.

Introduction: Benzodiazepines are currently the gold standard for treatment of alcohol withdrawal. Gabapentin has growing evidence to support its use in the treatment of alcohol use disorder, however there is limited evidence regarding its role in the treatment of alcohol withdrawal. The purpose of this study was to determine if adjunctive gabapentin reduces the need for benzodiazepine (BZD) administration during alcohol withdrawal. Read More

View Article

Download full-text PDF

Source
February 2019

Administration of Sub-anesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients with Treatment Resistant Depression: A Double Blind Placebo Controlled Trial.

Psychopharmacol Bull 2019 Feb;49(1):8-16

Altinay, MD, Karne, BS, Anand, MD, Center for Behavioral Health, Cleveland Clinic, Cleveland, ohio.

Introduction And Background: Patients with depression who fail to respond to at least two antidepressants in their current episode are considered to have Treatment Resistant Depression (TRD). ECT is an effective treatment of TRD but cognitive side effects limit its use. Ketamine elicits a rapid antidepressant response in sub-anesthetic repeated doses. Read More

View Article

Download full-text PDF

Source
February 2019

Retraction.

Authors:

Psychopharmacol Bull 2018 Jun;48(4):81

[This retracts the article on p. 8 in vol. 47. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294424PMC
June 2018
3 Reads

Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Psychopharmacol Bull 2018 Jun;48(4):62-80

Earley, MD, Associate Vice President, Clinical Development, Allergan, plc., Madison, New Jersey, USA. Guo, PhD, Director, Biostatistics, Allergan, plc., Madison, New Jersey, USA. Németh, MD, Chief Medical Officer, Medical Division, Gedeon Richter Plc, Budapest, Hungary. Harsányi, MD, Clinical Project Manager, Clinical Development Unit of Central Nervous System, Gedeon Richter Plc, Budapest, Hungary. Thase, MD, Professor of Psychiatry, Director, Mood and Anxiety Program, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Cariprazine is an atypical antipsychotic currently under investigation as an adjunctive to antidepressant treatment (ADT) for patients with major depressive disorder (MDD). Here results of an 18- to 19-week randomized double-blind placebo-controlled Phase 3 study evaluating the efficacy of adjunctive cariprazine (1.5-4. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294423PMC
June 2018
3 Reads

Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis.

Psychopharmacol Bull 2018 Jun;48(4):25-61

Medrano, MD, Clinique JAP, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada, and CHUM research centre, Montreal, Quebec, Canada. Abdel-Baki, MD, MSc, Clinique JAP, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada, Department of Psychiatry, Université de Montréal, Montreal, Quebec, Canada, and CHUM research centre, Montreal, Quebec, Canada. Stip, MD, and Potvin, PhD, Department of Psychiatry, Université de Montréal, Montreal, Quebec, Canada, and Centre de recherche Fernand-Séguin, Institut universitaire en santé mentale de Montréal, Montreal, Quebec, Canada.

Abstract: Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psychosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these studies represent a minority of patients who may benefit from LAI-AP. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294417PMC
June 2018
2 Reads

A Case of Hyper Sexuality Probably Associated with Clozapine.

Psychopharmacol Bull 2018 Jun;48(4):20-24

Thomson, MBBS, Post graduate student, Department of Pharmacology, Kasturba Medical College, Manipal Campus, Manipal University, Karnataka, India. Patil, Associate Professor, MBBS, MD, Department of Pharmacology, Kasturba Medical College, Manipal Campus, Manipal University, Karnataka, India. Ommurugan, MBBS, Post graduate student, Department of Pharmacology, Kasturba Medical College, Manipal Campus, Manipal University, Karnataka, India. Bhandary, MBBS, Associate Professor, Department of Psychiatry, Kasturba Medical College, Manipal Campus, Manipal, India.

Introduction: Schizophrenia treatment needs to cover several psychological interventions and pharmacological treatment for stabilizing the disease course and decreasing relapses. Sexual side effects are a major hindrance to patients and lead to decreased adherence to therapy and reduced quality of life. Recently, several studies outlined that sexual dysfunction is one of the most distressing side effects of antipsychotics and a major cause of a poor quality of life. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294421PMC
June 2018
7 Reads

Induction of Psychosis by Cyclobenzaprine.

Psychopharmacol Bull 2018 Jun;48(4):15-19

Cohen, MD, Guilbault, Psychiatry department, University of Montreal, Canada.

Due to the stringent regulatory environment for therapeutics, common side-effects of drugs in the general population are largely well-documented. This is however less the case with certain patient subgroups who may exhibit significant adverse responses to therapeutics that are otherwise well-tolerated. We report a case of psychosis induced by exposure to a commonly prescribed drug to treat muscle spasms and associated pain cyclobenzaprine (Flexeril®). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294419PMC
June 2018
3 Reads

The Utilization of Atypical Antipsychotics in the Pain Medicine Physician's Armamentarium.

Authors:
Omar Viswanath

Psychopharmacol Bull 2018 Jun;48(4):13-14

Viswanath, MD, Harvard Medical School, Department of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294418PMC
June 2018
3 Reads

A Perspective on Adolescent Chronic Pain Dismissal.

Psychopharmacol Bull 2018 Jun;48(4):10-12

Peck, MD, Department of Anesthesiology, Pediatric Anesthesiology, Pediatric Anesthesiology Clinical and Research Fellow, Johns Hopkins All Children's Hospital, St. Petersburg, FL. Viswanath, MD, Harvard Medical School, Department of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294422PMC
June 2018
1 Read

Re: An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature.

Psychopharmacol Bull 2018 Jun;48(4):8-9

Almeida, MD, Burrell Ward, MD, Brigham and Women's Hospital/Harvard Medical School, Department of Psychiatry, Division of Women's Mental Health, Boston, MA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294420PMC
June 2018
1 Read

Risperidone Induced Isolated Thrombocytopenia: A Rare Adverse Event.

Psychopharmacol Bull 2018 Mar;48(3):47-49

Bhattacharjee, MD, Department of Pharmacology, Kasturba Medical College, Manipal Campus, Manipal University, Karnataka, India. Yerrapragada, Undergraduate Candidate (MBBS), Kasturba Medical College, Manipal Campus, Manipal University, Karnataka, India. Chogtu, MD, Department of Pharmacology, Kasturba Medical College, Manipal Campus, Manipal University, Karnataka, India. Thomson, MBBS, Department of Pharmacology, Kasturba Medical College, Manipal Campus, Manipal University, Karnataka, India.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875368PMC
March 2018
43 Reads

Progressive Non-familial Adult onset Cerebellar Degeneration: An Unusual Occurrence with Hashimoto's Thyroiditis.

Psychopharmacol Bull 2018 Mar;48(3):42-46

Drs. Rao, Sheshadri, Rao, (Internal Medicine), Department of Internal Medicine, Kasturba Medical College, MAHE, Manipal, India. Drs. Bhattacharjee, Patil, (Pharmacology), Department of Pharmacology, Kasturba Medical College, MAHE, Manipal, India.

Progressive non-familial adult onset cerebellar degeneration has been rarely associated with hypothyroidism and is known to be reversible after therapy. We report a case of cerebellar atrophy in a 31 year old female whose detailed evaluation had revealed sub-clinical hypothyroidism secondary to autoimmune thyroiditis with a very high anti-TPO (anti-thyroid peroxidase) antibody levels. MRI (Magnetic Resonanace Imaging) of brain showed diffuse bilateral cerebellar atrophy. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875367PMC
March 2018
6 Reads

Efficacy and Tolerability of Two Different Kinds of Titration of Paroxetine Hydrocloride Solution: an Observational Study.

Psychopharmacol Bull 2018 Mar;48(3):33-41

Ielmini, Caselli and Bianchi, Medical Doctor at the Department of Medicine and Surgery, Psychiatry, University of Insubria, Via Guicciardini 2, 21100 Varese, Italy. Poloni, Universitary Researcher at the Department of Medicine and Surgery, Psychiatry, University of Insubria, Via Guicciardini 2, 21100 Varese, Italy. Diurni, PhD and Medical Doctor at the Department of Medicine and Surgery, Psychiatry, University of Insubria, Via Guicciardini 2, 21100 Varese, Italy. Vender, Honorary Professor at the University of Insubria, Via Guicciardini 2, 21100 Varese, Italy. Callegari, Associate Professor at the Department of Medicine and Surgery, Psychiatry, University of Insubria, Via Guicciardini 2, 21100 Varese, Italy.

Background: Depressive disorders are expected to be the second highest cause of morbidity in the world until few years. Moreover, patients with depression frequently show many side effects and low compliance to therapy. To find a more tolerated and more efficacy therapy is a growing need. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875366PMC
March 2018
8 Reads

A Case of Concomitant Pseudocyesis and Couvade Syndrome Variant.

Psychopharmacol Bull 2018 Mar;48(3):29-32

Mannekote Thippaiah, MD, Assistant Professor of Psychiatry, Zucker Hillside Hospital, NY. George, MD, Director, Otsuka Pharmaceuticals, Development & Commercialization, Inc., Philadelphia, PA. Birur, MD, Assistant Professor of Psychiatry, University of Alabama, Birmingham, AL. Pandurangi, MD, Virginia Commonwealth University, Department of Psychiatry Professor and Vice Chair, Richmond, VA 23298.

Per DSM-V, pseudocyesis is included under the category "other specified somatic symptom and related disorder" and is defined as a false belief of being pregnant that is associated with objective signs and reported symptoms of pregnancy. The male counterpart of pseudocyesis is Couvade syndrome, also called "sympathetic pregnancy" where a man experiences symptoms of pregnancy when his female partner is pregnant. There are extensive reports on pseudocyesis and Couvade syndrome in psychiatric literature but none with features of both, in a single case. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875365PMC
March 2018
8 Reads

Major Depressive Disorder Following Dermatomyositis: A Case Linking Depression with Inflammation.

Psychopharmacol Bull 2018 Mar;48(3):22-28

Reddy, MD, Birur, MD, Shelton, MD, Li, MD, Department of Psychiatry and Behavioral Neurobiology, University of Alabama, Birmingham, AL, 35294.

Major depressive disorder (MDD) is one of the most common psychiatric disorders. Recent studies have shown a strong association between MDD and peripheral inflammation, shown by a higher incidence of depression in patients with inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus. Dermatomyositis (DM), an idiopathic inflammatory connective tissue disease that is associated with inflammation, predominantly affects the skin and skeletal muscle. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875364PMC
March 2018
5 Reads

An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature.

Psychopharmacol Bull 2018 Mar;48(3):16-21

Thippaiah, MD, Assistant Professor in Psychiatry, Zucker Hillside Hospital, New Hyde Park, NY. Nagaraja, MD, Brookdale University Hospital & Medical Center, Brooklyn, NY. Birur, MD, Assistant Professor in Psychiatry, University of Alabama at Birmingham, AL. Cohen, MD, Professor of Obstetrics and Gynecology, Jefferson Medical College, Albert Einstein Medical Center, Philadelphia, PA.

Cyclical menstrual psychosis is an uncommon, generally a self-limiting mental illness that occurs only in females. It is associated with other menstruation-related disorders and stressful psychogenic factors. Nonetheless, many cases remain unrecognized due to poor awareness of its presence. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875363PMC
March 2018
4 Reads

Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?

Psychopharmacol Bull 2018 Mar;48(3):8-15

Maestri, PharmD, BCPP, Clinical Assistant Professor, Xavier University of Louisiana College of Pharmacy, New Orleans LA. Mican, PharmD, BCPP, Assistant Director of Pharmacy, Austin State Hospital, Clinical Assistant Professor, UT-Austin College of Pharmacy, Austin TX. Rozea, PharmD, PGY-1 Pharmacy Practice Resident, Michael E. DeBakey VA Medical Center, Houston TX. Barner, PhD, Professor, UT-Austin College of Pharmacy, Austin TX.

Introduction: Long-acting injectable (LAI) antipsychotics were developed as a way to decrease pill burden and simplify medication regimens by allowing less frequent administration to assist with medication adherence.

Methods: The purpose of this study was to determine whether LAI antipsychotics prevent or delay hospital readmission in patients with a known history of medication non-adherence. The study is a retrospective evaluation of 240 men and women 18-65 years of age diagnosed with bipolar disorder, schizophrenia, or schizoaffective disorder discharged from an inpatient state hospital over a 2 year period of time on a LAI antipsychotic (fluphenazine LAI, haloperidol LAI, risperidone LAI or paliperidone LAI) or oral antipsychotic. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875369PMC
March 2018
4 Reads

Dosing and Monitoring: Children and Adolescents.

Authors:
Glenn S Hirsch

Psychopharmacol Bull 2018 Feb;48(2):34-92

Dr. Hirsch is Vice Chair for Clinical Affairs, Department of Child and Adolescent Psychiatry and Child Study Center of the Hassenfeld Children's Hospital at NYU Langone and Associate Professor of Child and Adolescent Psychiatry, Psychiatry, and Pediatrics.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875361PMC
February 2018
2 Reads

Successful Management of Psychotropics Induced Stuttering Priapism with Pseudoephedrine in a Patient with Schizophrenia.

Psychopharmacol Bull 2018 Feb;48(2):29-33

Dr. Thippaiah, Assistant Professor in Psychiatry, Zucker Hillside Hospital, NY. Dr. Nagaraja, Brookdale University Hospital & Medical Center, Brooklyn, NY. Dr. Birur, Assistant Professor, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham. Dr. Pandurangi, Professor and Vice Chair, Virginia Commonwealth University, Department of Psychiatry, Richmond, VA.

Stuttering Priapism is a recurrent, persistent penile erection in the absence of sexual desire due to altered genital hemodynamics, affecting the arterial component (high flow, non-ischemic) or the veno-occlusive mechanism (low flow, ischemic). Both typical and atypical antipsychotics increase the risk for priapism with greater implications in typicals than atypicals. Prompt recognition and treatment are important as 40% to 50% of patients with stuttering priapism may develop an erectile dysfunction if left untreated. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875360PMC
February 2018
7 Reads

A Pilot Evaluating Clinical Pharmacy Services in an Ambulatory Psychiatry Setting.

Psychopharmacol Bull 2018 Feb;48(2):18-28

Lindell, PharmD, BCACP, Clinical Ambulatory Pharmacist, Michigan Medicine, Ann Arbor, MI. Stencel, PharmD Candidate 2018, Pharmacy Student, University of Michigan College of Pharmacy, Ann Arbor, MI. Ives, PharmD Candidate 2018, Pharmacy Student, University of Michigan College of Pharmacy, Ann Arbor, MI. Ward, PharmD, Clinical Assistant Professor, University of Michigan College of Pharmacy, Ann Arbor, MI. Fluent, Clinical Associate Professor, University of Michigan Medical School, Department of Psychiatry Faculty, Ambulatory Psychiatry, Ann Arbor, MI. Choe, PharmD, Associate Dean for Pharmacy Innovations and Partnerships and Clinical Associate Professor of Pharmacy, University of Michigan College of Pharmacy, and Director of Pharmacy Innovations and Partnerships, U-M Medical Group, Ann Arbor, MI.

Objectives: A pilot of clinical services provided by psychiatric clinical pharmacists in an outpatient clinic are described and evaluated. The primary objective was to evaluate the difference in change of Patient Health Questionnaire (PHQ)-9 and/or Generalized Anxiety Disorder (GAD) Questionnaire scores between the two groups. Secondary objectives were to assess time patients spent in clinic, time to target psychotropic medication dose, and patient self-reported medication adherence. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875359PMC
February 2018
5 Reads

Characterizing the Effects of Quetiapine in Military Post-Traumatic Stress Disorder.

Psychopharmacol Bull 2018 Feb;48(2):8-17

Dr. Villarreal, Behavioral Health Care Line (BHCL), Raymond G. Murphy VA Medical Center, Albuquerque, New Mexico, and Departments of Psychiatry and Neurosciences, University of New Mexico School of Medicine, New Mexico. Dr. Hamner, MD, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina and the Ralph H. Johnson Department of Veterans Affairs Charleston, S.C. Dr. Cañive, Departments of Psychiatry and Neurosciences, University of New Mexico School of Medicine, New Mexico. Dr. Qualls, Biomedical Research Institute of New Mexico and Department of Mathematics and Statistics, University of New Mexico, New Mexico.

Objectives: A previous randomized placebo-controlled trial in military veterans posttraumatic stress disorder (PTSD) found that quetiapine improved global PTSD symptoms severity, depression and anxiety as well as the re-experiencing and hypearousal clusters. However, it is not known if individual symptoms had a preferential response to this medication. The goal of this study was to analyze the individual symptom response in this group of patients. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875362PMC
February 2018
5 Reads

Retraction.

Authors:

Psychopharmacol Bull 2018 01;48(1):154

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765432PMC
January 2018
5 Reads

The Black Book of Psychotropic Dosing and Monitoring.

Psychopharmacol Bull 2018 Jan;48(1):64-153

Dr. Schatzberg, is chairman and Kenneth T. Norris, Jr. professor in the Department of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, Stanford, California. Dr. DeBattista, is professor of Psychiatry and Behavioral Sciences; co-director, Depression Research Clinic and Research Program; director, Mood Disorders Center; director, Medical Student Education in Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765435PMC
January 2018
5 Reads

The Use of Complementary Alternative Medicine in Children and Adolescents with Autism Spectrum Disorder.

Psychopharmacol Bull 2018 Jan;48(1):40-63

Dr. DeFilippis, Director, Child and Adolescent Division, Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch.

Complementary alternative medicine (CAM) is used to a greater degree in children and adolescents with autism spectrum disorder (ASD), when compared to children and adolescents without this diagnosis. There is limited evidence supporting the use of many of these treatments in ASD, despite their popularity. Current FDA approved medications for ASD target associated behavioral symptoms of the diagnosis, not the core symptoms of social communication deficits and restricted/repetitive behaviors. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765434PMC
January 2018
3 Reads

Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries.

Psychopharmacol Bull 2018 Jan;48(1):26-39

Drs. Tegin, Gulay, El-Mallakh, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine Louisville, Kentucky.

Objective: One of the possible explanations for the antidepressant resistance is tolerance to the effect of increasing synaptic serotonin. Vortioxetine is thought to work through a combination of two pharmacological modes of action: serotonin reuptake inhibition and modification of serotonin receptor activity, in a dose-dependent manner. This mechanism of action allows for examination of the hypothesis that antidepressant non-response may be due to exposure to persistently elevated synaptic amine levels. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765433PMC
January 2018
8 Reads

Major Depression Comorbid with Medical Conditions: Analysis of Quality of Life, Functioning, and Depressive Symptom Severity.

Psychopharmacol Bull 2018 Jan;48(1):8-25

Drs. IsHak, Dang, Vanle, Elzahaby, Reid, Sumner, Danovitch, and Ms. Klimowicz, Kauzor, Cedars-Sinai Medical Center, Los Angeles, California, USA. Dr. Steiner, University of California, Los Angeles, California, USA. Ms. Klimowicz, Western University of Health Sciences, California, USA. Ms. Kauzor, California State University, Northridge, California, USA.

Background: The presence of Major Depressive Disorder (MDD) is often comorbid in patients with a variety of general medical conditions (GMCs) which could lead to less favorable outcomes.

Objective: The goal of this analysis is to examine functional outcomes of QOL and functioning before and after antidepressant treatment among patients with MDD with and without GMCs.

Methods: We performed a secondary analysis based on the STAR*D database. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765436PMC
January 2018
19 Reads

Escitalopram Induced SIADH in an Elderly Female: A Case Study.

Psychopharmacol Bull 2017 Sep;47(4):64-67

Drs. Sudha, Karthik, Muralidhar, Aswini, Department of Internal Medicine, Kasturba Medical College, Manipal University, Manipal, India. Drs. Navin, Dipanjan, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, India.

Hyponatraemia is a well-established and potentially, a life-threatening adverse effect of selective serotonin receptor uptake inhibitors (SSRI). However, its occurrence secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) with escitalopram, has been reported extremely sporadically. The reporting of such rare, but life-threatening adverse effects of escitalopram assumes immense significance in light of the fact that SSRIs presently form the mainstay of treatment of depressive disorders. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601091PMC
September 2017
6 Reads

Dextromethorphan in Cough Syrup: The Poor Man's Psychosis.

Psychopharmacol Bull 2017 Sep;47(4):59-63

Dr. Martinak, MD, PGY3 Psychiatry Resident, Department of Psychiatry and Behavioral Neurobiology, University of Alabama, Birmingham. Mr. Bolis, MS-4, Medical Student-4, University of Alabama at Birmingham, Birmingham. Mr. Black, MS-4, Medical Student-4, University of Alabama at Birmingham, Birmingham. Dr. Fargason, MD, Professor, Department of Psychiatry and Behavioral Neurobiology, University of Alabama, Birmingham. Dr. Birur, MD, Assistant Professor, Department of Psychiatry and Behavioral Neurobiology, University of Alabama, Birmingham.

Dextromethorphan (3-methoxy-N-methylmorphinan), also known as "DXM" and "the poor man's PCP," is a synthetically produced drug that is available in more than 140 over-the-counter cough and cold preparations. Dextromethorphan (DXM) has overtaken codeine as the most widely used cough suppressant due to its availability, efficacy, and safety profile at directed doses. However, DXM is subject to abuse. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601090PMC
September 2017
55 Reads

Collaborative Care in Ambulatory Psychiatry: Content Analysis of Consultations to a Psychiatric Pharmacist.

Psychopharmacol Bull 2017 09;47(4):41-46

Drs. Gotlib, MD, Calip, MD, and Fluent, MD, Michigan Medicine, Department of Psychiatry, Ann Arbor, MI. Dr. Bostwick, PharmD, BCPS, BCPP, University of Michigan College of Pharmacy, Ann Arbor, MI. Dr. Perelstein, BS, Washington St. Louis School of Medicine, Department of Neurology, St. Louis, Missouri. Dr. Kurlander, MD, MS, Michigan Medicine, Division of Gastroenterology, Ann Arbor, MI.

Objectives: To determine the volume and nature (or topic) of consultations submitted to a psychiatric pharmacist embedded in an ambulatory psychiatry clinic, within a tertiary care academic medical center and to increase our understanding about the ways in which providers consult with an available psychiatric pharmacist.

Experimental Design: Authors analyze and describe the ambulatory psychiatric pharmacist consultation log at an academic ambulatory clinic. All consultation questions were submitted between July 2012 and October 2014. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601088PMC
September 2017
22 Reads

Physical Activity Diminishes Symptomatic Decline in Chronic Schizophrenia: A Systematic Review.

Psychopharmacol Bull 2017 09;47(4):29-40

Mr. Tarpada, BA, and Morris, BA, Albert Einstein College of Medicine, Bronx, NY USA.

Physical activity has been shown to positively influence a number of parameters in chronic schizophrenia, including cognition, social well being, and quality of life. Here, we present a systematic review of randomized controlled trials reporting on reduction of positive and negative symptoms using PANSS grading after the implementation of a physical activity protocol. Review of 64 articles yielded 6 relevant to our discussion. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601086PMC
September 2017
25 Reads

A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

Psychopharmacol Bull 2017 09;47(4):36-40

Drs. Dammerman, MD, PhD, Kim, PharmD, Adera, MBChB, Schwarz, PhD, Braeburn Pharmaceuticals, Princeton, NJ.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601087PMC
September 2017
14 Reads

A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

Psychopharmacol Bull 2017 09;47(4):29-35

Drs. Dammerman, MD, PhD, Kim, PharmD, Adera, MBChB, Schwarz, PhD. Braeburn Pharmaceuticals, Princeton, New Jersey.

View Article

Download full-text PDF

Source
September 2017
27 Reads

Unmet Medication Coverage Needs among Adults with Attention Deficit/Hyperactivity Disorder (ADHD).

Psychopharmacol Bull 2017 Sep;47(4):18-28

Dr. Brown, Department of Psychiatry, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA. Mr. Flood, ICON plc, Gaithersburg, MD, USA. Mr. Sarocco, Atkins, Khachatryan, Shire, Lexington, MA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601085PMC
September 2017
9 Reads

Persisting Psychosocial Impairments in Adults Being Treated with Medication for Attention Deficit/Hyperactivity Disorder.

Psychopharmacol Bull 2017 Sep;47(4):8-17

Dr. Brown, Department of Psychiatry, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA. Mr. Flood, ICON plc, Gaithersburg, MD, USA. Mr. Sarocco, Atkins, Khachatryan, Shire, Lexington, MA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601092PMC
September 2017
6 Reads

Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia - .

Authors:

Psychopharmacol Bull 2017 Aug;47(3):77-109

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546554PMC
August 2017
2 Reads

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.

Psychopharmacol Bull 2017 Aug;47(3):69-76

Drs. Kane, Correll, Hofstra Northwell School of Medicine, Hempstead, NY; Drs. Liang, Burke, O'Brien, Neurocrine Biosciences, Inc., San Diego, CA.

Background: Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (TD). The KINECT 3 study (NCT02274558) evaluated the effects of VBZ on TD in subjects with schizophrenia/schizoaffective disorder (SCHZ) or mood disorder (mood disorder presented separately) who received up to 48 weeks of treatment.

Methods: KINECT 3 included: 6-week, double-blind, placebo (PBO)-controlled (DBPC) period (205 completers); 42-week VBZ extension (VE) period (124 completers): 4-week washout period (121 completers). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546553PMC
August 2017
58 Reads

Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.

Psychopharmacol Bull 2017 Aug;47(3):61-68

Dr. Josiassen, Translational Neuroscience, Conshohocken, PA; Dr. Kane, Hofstra Northwell School of Medicine, Hempstead, NY; Drs. Liang, Burke, O'Brien, Neurocrine Biosciences, Inc., San Diego, CA.

Background: The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. Studies with longer treatment duration (up to 48 weeks) were conducted to evaluate the long-term safety of this novel drug in subjects with TD.

Methods: The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT (NCT01688037: 6-week DBPC, 6-week open-label); KINECT 3 (NCT02274558: 6-week DBPC, 42-week blinded extension, 4-week drug-free follow-up); KINECT 4 (NCT02405091: 48-week open-label, 4-week drug-free follow-up). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546552PMC
August 2017
57 Reads

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.

Psychopharmacol Bull 2017 Aug;47(3):53-60

Dr. Correll, Hofstra Northwell School of Medicine, Hempstead, NY; Dr. Josiassen, Translational Neuroscience, Conshohocken, PA; Drs. Liang, Burke, O'Brien, Neurocrine Biosciences, Inc., San Diego, CA.

Background: Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (TD). The KINECT 3 study (NCT02274558) evaluated the effects of VBZ on TD in subjects with mood disorder or schizophrenia/schizoaffective disorder (SCHZ, presented separately) who received up to 48 weeks of treatment.

Methods: KINECT 3 included: 6-week, double-blind, placebo (PBO)-controlled (DBPC) period (205 completers); 42-week VBZ extension (VE) period (124 completers); 4-week washout period (121 completers). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546551PMC
August 2017
41 Reads

Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.

Psychopharmacol Bull 2017 Aug;47(3):44-52

Drs. Luo, Bozigian, Jimenez, Loewen, O'Brien, Neurocrine Biosciences, Inc., San Diego, CA.

Valbenazine (VBZ) is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia. The safety, tolerability and pharmacokinetics of VBZ following single and repeat once-daily (QD) dosing were evaluated in 2 randomized, single-center, double-blind studies in healthy male subjects. In the first study, 2 cohorts of 8 subjects were administered single doses (SD) of placebo (PBO; N = 2/period) or VBZ (N = 6/period; 1, 2, 5, or 12. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546550PMC
August 2017
18 Reads

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.

Psychopharmacol Bull 2017 Aug;47(3):35-43

Dr. Nasrallah, MD, Department of Psychiatry & Behavioral Neuroscience, Saint Louis School of Medicine, St Louis, MO, USA; Dr. Aquila, MD, Fountain House, New York City, NY, USA; Drs. Stanford, MD, Jamal, MSc, Weiden, MD, Risinger, MD, Clinical Development and Medical Affairs, Alkermes, Inc., Waltham, MA, USA; Dr. Jamal, MSc, Previously at Alkermes, Inc., Waltham, MA, USA; Dr. Risinger, MD, NeuroRx Pharmaceuticals, Wilmington, DE, USA.

Background: We assessed long-term metabolic and endocrine profiles of outpatients with schizophrenia participating in a one-year open-label extension study of monthly aripiprazole lauroxil (AL), a long-acting injectable antipsychotic.

Methods: Patients (N = 478) were enrolled in a 52-week, open-label extension study of AL monotherapy administered by intramuscular injection every 4 weeks. Of these, most (368) received AL 882 mg and the remainder AL 441 mg as their fixed-dose regimen. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546549PMC
August 2017
67 Reads

A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.

Psychopharmacol Bull 2017 Aug;47(3):26-34

Dr. Risinger, previously at Alkermes, Inc., Waltham, MA, USA; Drs. Hard, Weiden, Alkermes, Inc, Waltham, MA, USA; Dr. Hard, currently at Nuventra Pharma Sciences, Durham, NC, USA. Dr. Risinger, currently at NeuroRxPharmaceuticals, Wilmington, DE, USA.

Background: Aripiprazole lauroxil (AL) is an FDA-approved treatment for schizophrenia. AL is a non-ester prodrug of aripiprazole that results in extended systemic release of aripiprazole after intramuscular (IM) administration. This Phase-1 study evaluated the pharmacokinetics (PK) and safety of a new AL dose (1064 mg)* for 2-month dose intervals. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546548PMC
August 2017
20 Reads

Correlation of Caregiver Burden and Baseline Characteristics of Caregivers and Patients in Their Care with Recent-Onset Psychosis: The FIRST Study.

Psychopharmacol Bull 2017 Aug;47(3):17-25

Drs. Mancevski, Tardieu, Kim, Janssen Scientific Affairs, LLC, Titusville, NJ; Dr. Gogate, Janssen Research and Development, LLC, Titusville, NJ; Dr. Ashcroft, Healios, Inc, High Bridge, NJ.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546547PMC
August 2017
20 Reads